Tianjin Medical University Cancer Institute and Hospital: Carcinoma trials

The registry lists 39 Carcinoma studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 19 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 28Phase 3 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular CarcinomaNot yet recruitingNCT06867432Phase 2
• Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsRecruitingNCT06489197Phase 2
• Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.RecruitingNCT06375486Phase 2
• Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT06370065Phase 2
• Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety StudyRecruitingNCT06301399Phase 2
• Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine CarcinomaRecruitingNCT06102746
• H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein ThrombosisNot yet recruitingNCT05872841Phase 2
• HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2
• Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
• HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular CarcinomaNot yet recruitingNCT05821361Phase 2
• Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular CarcinomaRecruitingNCT05616390Phase 2
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
• A Phase II Study of CRT Combined With QL1706 in ESCC PatientsRecruitingNCT05490719Phase 2
• Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT05449483Phase 2
• Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3
• Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal CancerNot yet recruitingNCT03367884Not applicable
• XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingNCT03355612Phase 3
• Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT06241079
• The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell CarcinomaCompletedNCT06241066
• Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652
• Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous CarcinomaStatus unknownNCT05854030
• Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
• Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Phase 2
• Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
• HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
• An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
• Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaStatus unknownNCT04834986Phase 2
• Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaCompletedNCT04701060Phase 2
• Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Phase 2
• PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCCStatus unknownNCT04273100Phase 2
• To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing ChemoradiotherapyCompletedNCT04199832
• Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell CarcinomaStatus unknownNCT03987698Phase 2
• Study of Apatinib Combined With TACE in Advance Hepatocellular CarcinomaStatus unknownNCT03398122Not applicable
• Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid CarcinomaStatus unknownNCT03167385Phase 2
• Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Phase 2
• A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.Status unknownNCT02774200Phase 2
• Metformin Plus Sorafenib for Advanced HCCStatus unknownNCT02672488Phase 2